⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALT News
Altimmune, Inc. Common Stock
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
globenewswire.com
ALT
Altimmune to Participate in Upcoming Investor Conferences
globenewswire.com
ALT
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
globenewswire.com
ALT
Altimetrik Recognized in 3 Categories in ISG Provider Lens™ 2026 for Life Sciences Digital Services
businesswire.com
ALT
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
globenewswire.com
AMGN
NVS
AUTL
CARG
ALT
REGN
GILD
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
globenewswire.com
MRK
ABBV
VKTX
ALT
Form 8-K
sec.gov
ALT
Altimmune Announces First Quarter 2026 Financial Results and Business Update
globenewswire.com
ALT
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
globenewswire.com
ALT
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
globenewswire.com
ALT